Short Course Radiation Therapy in Palliative Treatment of Esophageal Cancer
- Conditions
- RadiotherapyEsophageal CancerPalliative Care
- Interventions
- Radiation: standard treatmentRadiation: short course treatment
- Registration Number
- NCT03804203
- Brief Summary
Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic esophageal malignant lesions
- Detailed Description
Standard treatment for esophageal lesions (3000 cGy in 10 daily fractions of 300 cGy each) is compared with experimental treatment (2000 cGy in 4 fractions of 500 cGy twice a day) to demonstrate non-inferiority of this scheme
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 98
- symptomatic esophageal malignant lesions (primary solid tumors or metastases from solid tumor);
- age>18 years;
- ECOG performance status 0-3
- no changes in supportive care in the week before radiotherapy
- pregnancy
- previous irradiation of the same region
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description standard treatment standard treatment patients in this group are treated with 3000 cGy in 10 daily fraction short course treatment short course treatment patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
- Primary Outcome Measures
Name Time Method Efficacy of palliation using the short course scheme compared with the standard scheme: Likert scale 3 months reduction of initial symptoms after radiotherapy, assessed with Likert scale (dysphagia, odynophagia, regurgitation, chest-back pain are evaluated as none-mild-moderate-severe)
- Secondary Outcome Measures
Name Time Method late toxicity in the two treatment groups 12 months incidence of treatment-related adverse events in the two arms of the study registered using RTOG/EORTC Late Radiation Morbility Scoring Schema
acute toxicity in the two treatment groups 3 months incidence of treatment-related acute adverse events in the two arms of the study registered using Cooperative Group Common Toxicity Criteria
Quality of Life (QoL): EORTC questionnaire C15-PAL 12 months changes in QoL after the treatment assessed using European Organization for Research and Treatment of Cancer (EORTC) questionnaire C15-PAL (a specific questionnaire from EORTC developed to assess the quality of life of palliative cancer care patients)
Trial Locations
- Locations (1)
Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital
🇮🇹Bologna, BO, Italy